AZNAstraZenecaSigning up patients
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 232 (planned)
- Started
- Jul 20, 2023
- Main results expected
- Oct 1, 2027
- Fully finished
- Jan 25, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1b: Adverse Events (AEs)
Measured over: Through study completion, a minimum of 2 years.
Phase 1b: Dose-Limiting Toxicities (DLTs)
Measured over: 28 days
Phase 2: Objective Response Rate (ORR)
Measured over: Through study completion, a minimum of 2 years.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05850234 · record last updated 2026-10-08 · checked 2026-11-09 15:47 UTC